Development of uterine sarcoma after tamoxifen treatment for breast cancer: Report of four cases

International Journal of Gynecological Cancer

Volumn 15, Issue 6, 2005, Pages 1239-1242

  Yildirim, Yusuf ^a,c   Inal, M M ^a   Sanci, M ^a   Yildirim, Y K ^b   Mit, T ^a   Polat, M ^a   Tinar, S ^a  

^a Aegean Obstetrics and Gynecology Teaching and Research Hospital   (Turkey)

^b EGE UNIVERSITY   (Turkey)

^c Palmiye Sit Bahar Mah   (Turkey)

Author keywords

Endometrial pathologies; Tamoxifen; Uterine sarcomas

Indexed keywords

ANTINEOPLASTIC AGENT; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CASE REPORT; DRUG DOSE REGIMEN; DRUG EXPOSURE; ENDOMETRIUM BIOPSY; FEMALE; GYNECOLOGICAL EXAMINATION; HUMAN; LEIOMYOSARCOMA; LONG TERM CARE; PELVIS; POSTMENOPAUSE; PRIORITY JOURNAL; TRANSVAGINAL ECHOGRAPHY; UTERUS SARCOMA; VAGINA BLEEDING;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COMBINED MODALITY THERAPY; FATAL OUTCOME; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; LEIOMYOSARCOMA; MASTECTOMY; MIDDLE AGED; MIXED TUMOR, MULLERIAN; TAMOXIFEN; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 30944437587     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.00170.x     Document Type: Article

References (38)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. An overview of the randomized trials. Lancet 1998;351:1451-67.
2. Juneja M, Jose R, Kekre AN, Viswarathan F, Seshadri L. Tamoxifen induced endometrial changes in postmenopausal women with breast carcinoma. Int J Gynaecol Obstet 2002;76:279-84.
3. Fornander T, Rutqvist LE, Cedermark B et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;2:117-20.
4. Fisher B, Dignam J, Wolmark N et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet 1999;353: 1993-2000.
5. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-I study. J Natl Cancer Inst 1998;90:1371-88.
6. Varras M, Polyzos D, Akrivis Ch. Effects of tamoxifen on the human female genital tract: review of the literature. Eur J Gynaecol Oncol 2003;24:258-68.
7. Rullo S, Tagliaferri T, Bandiera F et al. Uterine changes during tamoxifen therapy. Clin Exp Obstet Gynecol 1993;20:116-9.
8. Wilking N, Isaksson E, von Schoultz E. Tamoxifen and secondary tumors. An update. Drug Saf 1997;16:104-17.
9. Rutavist LE. Long-term toxicity of tamoxifen. Recent Results Cancer Res 1993;127:257-66.
10. Clement PB, Oliva E, Young RH. Mullerien adenosarcoma of uterine corpus associated with tamoxifen therapy: a review of six cases and a review of tamoxifen associated endometrial lesions. Int J Gynecol Pathol 1996;15:222-9.
11. Sabatini R, DiFazio F, Loizzi P. Uterine leiomyosarcoma in a postmenopausal woman treated with tamoxifen, case report. Eur J Gynaecol Oncol 1999;20:327-8.
12. McCluggage WG, Abdulkader M, Price JH et al. Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases. Int J Gynecol Cancer 2000;10:280-4.
13. El Husseiny G, Al Bareedy N, Mourad WA et al. Prognostic factors and treatment modalities in uterine sarcoma. Am J Clin Oncol 2002;25:256-60.
14. Bodner K, Bodner AB, Kimberger O et al. Evaluating prognostic parameters in women with uterine leiomyosarcoma. A clinicopathologic study. J Reprod Med 2003;48:95-100.
15. Ansbacher R, Advincula AP. Endometrial polyp secondary to tamoxifen therapy. Fertil Steril 2003;80:216.
16. Wickerman LD, Fisher B, Wolmark N. Association of tamoxifen and uterine sarcoma. J Clin Oncol 2002;20:2756-61.
17. Kloos I, Delaloge S, Pautier P et al. Tamoxifen related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature. Int J Gynecol Cancer 2002;12: 496-500.
18. Gottlieb S Tamoxifen may increase risk of uterine sarcoma. BMJ 2002;325:7.
19. Seoud MAF, Johnson J, Weed JC. Gynecologic tumors in tamoxifen treated women with breast cancer. Obstet Gynecol 1993;82:165-9.
20. McCluggage WG, Varma M, Weir P, Bharucha H. Uterine leiomyosarcoma in patient receiving tamoxifen therapy. Acta Obstet Gynecol Scand 1996;75:593-5.
21. Saga Y, Ohwada M, Kohno T, Takayashiki N, Suziki M. High-grade endometrial stromal sarcoma after treatment with tamoxifen in a patient treated for breast cancer. Int J Gynecol Cancer 2003;13:690-2.
22. Le Bouedec G, Auvray H, Cure H et al. Uterine sarcoma in patients receiving tamoxifen therapy. Apropos of 2 cases. Rev Med Interne 2001;22:881-5.
23. Cohen I, Bernheim J, Azaria R et al. Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients. Gynecol Oncol 1999;75:136-44.
24. Al-Azemi M, Labib NS, Motawy MM et al. Prevalence of endometrial proliferation in pipelle biopsies in tamoxifen-treated postmenopausal women with breast cancer in Kuwait. Med Princ Pract 2004;13:30-4.
25. Rutqvist LE. Adjuvant endocrine therapy. Best Pract Res Clin Endocrinol Metab 2004;18:81-95.
26. Rea D, Poole C, Gray R. Adjuvant tamoxifen: how long before we know how long? BMJ 1998;316:1518-9.
27. Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol 1994;47:827-33.
28. Fotious S, Hatjieleftheriou G, Kyrousis G, Kokka F, Apostolikas N. Long-term tamoxifen treatment: a possible etiologic factor in the development of uterine carcinosarcoma: two case-reports and review of the literature. Anticancer Res 2000;20:2015-20.
29. Grady D, Gebretsadik T, Kerlikowske K et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-13.
30. Weiderpass E, Adami HO, Baron JA et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131-7.
31. Stearns V, Gelmann EP. Does tamoxifen cause cancer in humans? J Clin Oncol 1998;16:779-92.
32. Martin EA, Brown K, Gaskell M et al. Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res 2003;63:8461-5.
33. Giorda G, Franceschi L, Crivellari D et al. Determination of tamoxifen and its metabolites in the endometrial tissue of long-term treated women. Eur J Cancer 2000;36:88-9.
34. Mourits MJE, DeVries EGE, Willemse PHB et al. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 2001;97: 855-66.
35. Lhomme C, Pautier P, Zagame L et al. Endometrial surveillance of women on tamoxifen. Gynecol Obstet Fertil 2003;31:647-56.
36. Committee Opinion, American College of Obstetricians and Gynecologists, Number 232, April 2000.
37. Ito T, Katagiri C, Murata Y, Hamazoe R, Marita K. Indication for histological examination of endometrium in breast carcinoma patients receiving tamoxifen therapy. J Obstet Gynaecol Res 2001;27:141-5.
38. Schwartz PE. Gynecologic surveillance of women on tamoxifen. Conn Med 1994;58:515-21.